Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Shin KH et al. | Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance. | 2013 | Clin. Pharmacol. Ther. | pmid:23784264 |
van de Merbel NC and de Vries R | Aging of biological matrices and its effect on bioanalytical method performance. | 2013 | Bioanalysis | pmid:24066624 |
Xu Y et al. | LC-ESI-MS/MS quantification of 4β-hydroxycholesterol and cholesterol in plasma samples of limited volume. | 2013 | J Pharm Biomed Anal | pmid:23948760 |
Suzuki Y et al. | Association of plasma concentration of 4β-hydroxycholesterol with CYP3A5 polymorphism and plasma concentration of indoxyl sulfate in stable kidney transplant recipients. | 2014 | Drug Metab. Dispos. | pmid:24135442 |
Dutreix C et al. | Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin. | 2014 | Eur. J. Clin. Pharmacol. | pmid:24839948 |
Nylén H et al. | Plasma levels of 25-hydroxyvitamin D3 and in vivo markers of cytochrome P450 3A activity in Swedes and Koreans: effects of a genetic polymorphism and oral contraceptives. | 2014 | Basic Clin. Pharmacol. Toxicol. | pmid:24655660 |
Li K et al. | 4β-Hydroxycholesterol as an endogenous biomarker of CYP3A activity in cynomolgus monkeys. | 2014 | Drug Metab. Dispos. | pmid:24595680 |
Ngaimisi E et al. | Pharmacokinetic and pharmacogenomic modelling of the CYP3A activity marker 4β-hydroxycholesterol during efavirenz treatment and efavirenz/rifampicin co-treatment. | 2014 | J. Antimicrob. Chemother. | pmid:25096076 |
Huang MQ et al. | Quantitation of P450 3A4 endogenous biomarker - 4β-hydroxycholesterol - in human plasma using LC/ESI-MS/MS. | 2014 | Biomed. Chromatogr. | pmid:24861746 |
Ikegami T et al. | Increased serum oxysterol concentrations in patients with chronic hepatitis C virus infection. | 2014 | Biochem. Biophys. Res. Commun. | pmid:24525121 |